Seeking Alpha
Research analyst, IPOs, long/short equity
Profile| Send Message|
( followers)

The following IPOs are expected to price this week:

Auris Medical (NASDAQ:EARS), a biotech developing treatments for tinnitus and other inner ear disorders, plans to raise $76 million by offering 6.9 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Auris Medical would command a market value of $285 million. Auris Medical, which was founded in 2003, booked $0 million in sales over the last 12 months. The Zug, Switzerland-based company plans to list on the NASDAQ under the symbol EARS. Jefferies & Co. and Leerink Partners are the joint bookrunners on the deal.

Green Bancorp (NASDAQ:GNBC), a Texas bank with 12 branches in the Houston, Dallas and Austin MSAs, plans to raise $75 million by offering 4.7 million shares at a price range of $15.00 to $17.00. At the midpoint of the proposed range, Green Bancorp would command a market value of $428 million. Green Bancorp, which was founded in 2006, booked $65 million in sales over the last 12 months. The Houston, TX-based company plans to list on the NASDAQ under the symbol GNBC. Sandler O'Neill and Jefferies & Co. are the joint bookrunners on the deal.

GWG Holdings (NASDAQ:GWGH), which holds a portfolio of life insurance policies worth over $250 million, plans to raise $20 million by offering 1.6 million shares at a price range of $11.50 to $13.50. At the midpoint of the proposed range, GWG Holdings would command a market value of $112 million. GWG Holdings, which was founded in 2006, booked $30 million in sales over the last 12 months. The Minneapolis, MN-based company plans to list on the NASDAQ under the symbol GWGH.

Hoegh LNG Partners LP (NYSE:HMLP), an MLP formed by Höegh LNG to own three floating storage and regasification units, plans to raise $192 million by offering 9.6 million shares at a price range of $19.00 to $21.00. At the midpoint of the proposed range, Hoegh LNG Partners LP would command a market value of $526 million. Hoegh LNG Partners LP, which was founded in 2014, booked $41 million in sales over the last 12 months. The Oslo, Norway-based company plans to list on the NYSE under the symbol HMLP. Citi, BofA Merrill Lynch, Morgan Stanley and Barclays are the joint bookrunners on the deal.

iDreamSky Technology (NASDAQ:DSKY), a Chinese mobile game publisher with 100 million monthly active users, plans to raise $100 million by offering 7.7 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, iDreamSky Technology would command a market value of $602 million. iDreamSky Technology, which was founded in 2009, booked $65 million in sales over the last 12 months. The Shenzhen, China-based company plans to list on the NASDAQ under the symbol DSKY. Credit Suisse, J.P. Morgan and Stifel are the joint bookrunners on the deal.

Independence Contract Drilling (NYSE:ICD), which operates nine contracted land drilling rigs for E&Ps in the Permian Basin, plans to raise $150 million by offering 10.0 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, Independence Contract Drilling would command a market value of $346 million. Independence Contract Drilling, which was founded in 2012, booked $48 million in sales over the last 12 months. The Houston, TX-based company plans to list on the NYSE under the symbol ICD. Morgan Stanley, RBC Capital Markets and Tudor, Pickering, Holt & Co. are the joint bookrunners on the deal.

Microlin Bio (NASDAQ:MCLB), a diagnostic and therapeutics biotech focusing on microRNA and its role in oncology, plans to raise $28 million by offering 5.5 million shares at a price range of $4.50 to $5.50. At the midpoint of the proposed range, Microlin Bio would command a market value of $51 million. Microlin Bio, which was founded in 2013, booked $0 million in sales over the last 12 months. The New York, NY-based company plans to list on the NASDAQ under the symbol MCLB. Brean Capital and Summer Street Research Partners are the joint bookrunners on the deal. Please note: Revised terms for the fourth time on 7/3/14 and added warrants. Originally planned to offer 3.6 million common shares at a range of $6-$8.

Ryerson Holding (NYSE:RYI), the second largest metals distributor in North America, plans to raise $204 million by offering 11.0 million shares at a price range of $17.00 to $20.00. At the midpoint of the proposed range, Ryerson Holding would command a market value of $593 million. Ryerson Holding, which was founded in 1842, booked $3.4 billion in sales over the last 12 months. The Chicago, IL-based company plans to list on the NYSE under the symbol RYI. BofA Merrill Lynch, Deutsche Bank, BMO Capital Markets and J.P. Morgan are the joint bookrunners on the deal. Please note: Previously set terms to go public in May 2010 at a $1.2 billion market cap.

T2 Biosystems (NASDAQ:TTOO), which is developing diagnostics tests that screen for sepsis and hemostasis, plans to raise $64 million by offering 4.0 million shares at a price range of $15.00 to $17.00. At the midpoint of the proposed range, T2 Biosystems would command a market value of $321 million. T2 Biosystems, which was founded in 2006, booked $0 million in sales over the last 12 months. The Lexington, MA-based company plans to list on the NASDAQ under the symbol TTOO. Goldman Sachs and Morgan Stanley are the joint bookrunners on the deal.

Tobira Therapeutics (NASDAQ:TBRA), a biotech developing an immunotherapy treatment for liver disease (NASH) and HIV, plans to raise $60 million by offering 4.6 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Tobira Therapeutics would command a market value of $150 million. Tobira Therapeutics, which was founded in 2006, booked $0 million in sales over the last 12 months. The San Francisco, CA-based company plans to list on the NASDAQ under the symbol TBRA. BMO Capital Markets, JMP Securities and Oppenheimer & Co. are the joint bookrunners on the deal.

Zosano Pharma (NASDAQ:ZSAN), a biotech developing a transdermal delivery system to treat osteoporosis, plans to raise $70 million by offering 6.4 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Zosano Pharma would command a market value of $139 million. Zosano Pharma, which was founded in 2007, booked $3 million in sales over the last 12 months. The Fremont, CA-based company plans to list on the NASDAQ under the symbol ZSAN. Wedbush PacGrow, Ladenburg Thalmann & Co. and Roth Capital are the joint bookrunners on the deal.

Last week, there were 15 IPO pricings. Mobileye (NYSE:MBLY), an Israeli developer of Advanced Driver Assistance Systems, and Avalanche Biotechnologies (NASDAQ:AAVL), an early-stage biotech developing a gene therapy for wet AMD, were the week's winners, ending up 48% from their IPO price.

Source: 11 U.S. IPOs Planned For The Week Of August 4